FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 467 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR 120 years of discovery: 10 ways we’ve changed the story for... February 2, 2022 When You Lose a Spouse to Cancer and Need Support February 25, 2021 How to Make the Most of Your Patient Portal During Cancer November 24, 2021 Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced,... July 28, 2026 Load more HOT NEWS EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment... Do Black Lives Matter Less Than Those of Cancer Survivors? Cliff Collapse Kills Woman Celebrating Breast Cancer Victory and 2 of... What Cancer Caregivers Should Know About Hospice Care at Home: A...
